Compare VIR & WD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | VIR | WD |
|---|---|---|
| Founded | 2016 | 1937 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance: Consumer Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.1B |
| IPO Year | 2019 | 2010 |
| Metric | VIR | WD |
|---|---|---|
| Price | $10.57 | $34.24 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 10 | 4 |
| Target Price | $21.00 | ★ $48.33 |
| AVG Volume (30 Days) | ★ 1.8M | 527.5K |
| Earning Date | 11-04-2026 | 11-05-2026 |
| Dividend Yield | N/A | ★ 7.84% |
| EPS Growth | ★ 17.49 | N/A |
| EPS | N/A | ★ 0.55 |
| Revenue | $68,556,000.00 | ★ $1,234,306,000.00 |
| Revenue This Year | $257.66 | $9.25 |
| Revenue Next Year | N/A | $9.48 |
| P/E Ratio | ★ N/A | $63.17 |
| Revenue Growth | N/A | ★ 8.99 |
| 52 Week Low | $4.82 | $31.40 |
| 52 Week High | $12.00 | $86.32 |
| Indicator | VIR | WD |
|---|---|---|
| Relative Strength Index (RSI) | 47.63 | 46.39 |
| Support Level | $10.00 | $31.40 |
| Resistance Level | $11.83 | $52.37 |
| Average True Range (ATR) | 0.62 | 1.55 |
| MACD | -0.08 | 0.41 |
| Stochastic Oscillator | 30.62 | 66.20 |
Vir Biotechnology Inc is a clinical-stage biopharmaceutical company focused on powering the immune system by discovering and developing medicines for serious infectious diseases and cancer. The company uses its capabilities in antibody discovery and engineering, coupled with its proprietary AI engine dAIsY system, and the PRO-XTEN masking platform, to quickly and effectively discover and optimize potential new medicines. Its clinical development pipeline consists of investigational therapies like Tobevibart + elebsiran targeting the hepatitis delta virus (HDV), preclinical antibody candidates targeting HIV, and VIR-5500, VIR-5818, VIR-5525, and 7 PRO-XTEN programs targeting multiple solid tumors. Currently, the company generates revenue mainly by issuing license rights and through grants.
Walker & Dunlop Inc is a United States-based commercial real estate finance company. It is principally engaged in originating, selling, and servicing a number of multifamily and other commercial real estate financing products that are sold under the programs of Freddie Mac, Fannie Mae, Ginnie Mae, and the Federal Housing Administration. The company is managed based on three reportable segments: Capital Markets (CM), Servicing & Asset Management (SAM), and Corporate. The company generates a majority of its total revenue from gains from mortgage banking activities and servicing fees. It conducts business solely in the United States.